Factors Associated with Lung Function Decline in Patients with Non-Tuberculous Mycobacterial Pulmonary Disease

Background There is paucity of risk factors on lung function decline among patients with non-tuberculous mycobacteria (NTM) pulmonary disease in literature. Methods Patients with NTM pulmonary disease between January 2000 and April 2011 were retrospectively selected. Sixty-eight patients had at least two pulmonary function tests within a mean follow-up period of 47 months. Results Sixty-eight patients were included. They had a median age of 65 years and 65% had impaired lung function (Forced expiratory volume in 1 second [FEV1] <80% of predicted value). The mean FEV1 decline was 48 ml/year. By linear regression, younger age (beta: 0.472, p<0.001), initial FEV1>50% of predicted value (beta: 0.349, p = 0.002), male sex (beta: 0.295, p = 0.018), bronchiectasis pattern (beta: 0.232, p = 0.035), and radiographic score >3 (beta: 0.217, p = 0.049) were associated with greater FEV1 decline. Initial FEV1>50% of predicted value (beta: 0.263, p = 0.032) was also associated with greater FVC annual decline, whereas M. kansasii pulmonary disease was marginally associated with greater annual FVC decline (beta: 0.227, p = 0.062). Conclusions NTM pulmonary disease is associated with greater decline in lung function in patients who are young, male, with bronchiectasis, and with a high radiographic score. Special attention should be given to patients with these risk factors.

[1]  M. Lebowitz,et al.  The "horse-racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. , 2015, The American review of respiratory disease.

[2]  G. Snider,et al.  Obstructive airway disease in patients with treated pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[3]  D. Shitrit,et al.  Clinical and radiological features of Mycobacterium kansasii and other NTM infections. , 2012, Respiratory medicine.

[4]  Meng-Rui Lee,et al.  Performance Assessment of the DR. TBDR/NTM IVD Kit for Direct Detection of Mycobacterium tuberculosis Isolates, Including Rifampin-Resistant Isolates, and Nontuberculous Mycobacteria , 2012, Journal of Clinical Microbiology.

[5]  D. Griffith,et al.  Bronchiectasis and nontuberculous mycobacterial disease. , 2012, Clinics in chest medicine.

[6]  M. Roberts,et al.  Limited lung function: impact of reduced peak expiratory flow on health status, health-care utilization, and expected survival in older adults. , 2012, American journal of epidemiology.

[7]  P-C. Yang,et al.  Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  Pan‐Chyr Yang,et al.  Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration. , 2012, The Journal of infection.

[9]  T. Marras,et al.  Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. , 2011, Respiratory medicine.

[10]  Chong-Jen Yu,et al.  Clinical Characteristics and Prognosis of Nontuberculous Mycobacterial Lung Disease with Different Radiographic Patterns , 2011, Lung.

[11]  Pan‐Chyr Yang,et al.  Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis , 2011, Clinics.

[12]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[13]  Albert Miller,et al.  Mycobacterium Avium Complex (MAC) Lung Disease in Two Inner City Community Hospitals: Recognition, Prevalence, Co-Infection with Mycobacterium Tuberculosis (MTB) and Pulmonary Function (PF) Improvements After Treatment , 2010, The open respiratory medicine journal.

[14]  Pan‐Chyr Yang,et al.  Use of High-Dose Inhaled Corticosteroids is Associated With Pulmonary Tuberculosis in Patients With Chronic Obstructive Pulmonary Disease , 2010, Medicine.

[15]  M. Weatherall,et al.  Quality of life measured by the St George's Respiratory Questionnaire and spirometry , 2009, European Respiratory Journal.

[16]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[17]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[18]  E. Picard,et al.  Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel , 2008, Emerging infectious diseases.

[19]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[20]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[21]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[22]  Jann-Yuan Wang,et al.  Performance Assessment of a Nested-PCR Assay (the RAPID BAP-MTB) and the BD ProbeTec ET System for Detection of Mycobacterium tuberculosis in Clinical Specimens , 2004, Journal of Clinical Microbiology.

[23]  R. Wallace,,et al.  Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria , 2002, Clinical Microbiology Reviews.

[24]  D M Hansell,et al.  A comparison of serial computed tomography and functional change in bronchiectasis , 2002, European Respiratory Journal.

[25]  R. Wallace,,et al.  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. , 1998, American journal of respiratory and critical care medicine.

[26]  D. Dockery,et al.  Longitudinal lung function decline in subjects with respiratory symptoms. , 1992, The American review of respiratory disease.

[27]  T A Louis,et al.  Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. , 1990, American journal of epidemiology.

[28]  P. Schnohr,et al.  Effects of smoking and changes in smoking habits on the decline of FEV1. , 1989, The European respiratory journal.

[29]  M. Lebowitz,et al.  Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. , 1987, The American review of respiratory disease.

[30]  M. Lebowitz,et al.  Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. , 1986, The American review of respiratory disease.

[31]  Pan‐Chyr Yang,et al.  Disseminated tuberculosis: a 10-year experience in a medical center. , 2007, Medicine.